• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Corcept Therapeutics Incorporated

    2/21/25 5:23:33 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CORT alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 16)


    CORCEPT THERAPEUTICS INC

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    218352102

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    218352102


    1Names of Reporting Persons

    INGALLS & SNYDER LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    NEW YORK
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    8,173,721.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    8,173,721.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.8 %
    12Type of Reporting Person (See Instructions)

    BD, IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    CORCEPT THERAPEUTICS INC
    (b)Address of issuer's principal executive offices:

    101 REDWOOD SHORES PARKWAY, REDWOOD CITY, CALIFORNIA, 94065
    Item 2. 
    (a)Name of person filing:

    INGALLS & SNYDER, LLC
    (b)Address or principal business office or, if none, residence:

    1 ROCKEFELLER PLAZA, NEW YORK NY 10020
    (c)Citizenship:

    NEW YORK
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    218352102
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    8,173,721
    (b)Percent of class:

    7.8%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    8,173,721

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Ingalls & Snyder, LLC ("I&S") is a registered broker dealer and a registered investment advisor. Shares reported under shared dispositive power include shares held in accounts managed under investment advisory contracts.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    INGALLS & SNYDER LLC
     
    Signature:THOMAS O BOUCHER JR
    Name/Title:MANAGING DIRECTOR
    Date:02/21/2025
    Get the next $CORT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CORT

    DatePrice TargetRatingAnalyst
    12/31/2025$30.00Peer Perform → Underperform
    Wolfe Research
    12/16/2025Neutral
    UBS
    11/18/2025Peer Perform
    Wolfe Research
    11/6/2023$29.00 → $38.00Hold → Buy
    Truist
    4/11/2023$25.00Market Perform
    SVB Securities
    4/4/2023$27.00Overweight
    Piper Sandler
    2/15/2023$35.00 → $22.00Buy → Hold
    Jefferies
    8/1/2022$30.00Buy → Hold
    Truist
    More analyst ratings

    $CORT
    SEC Filings

    View All

    SEC Form 8-K filed by Corcept Therapeutics Incorporated

    8-K - CORCEPT THERAPEUTICS INC (0001088856) (Filer)

    1/22/26 8:10:37 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Corcept Therapeutics Incorporated

    8-K - CORCEPT THERAPEUTICS INC (0001088856) (Filer)

    12/31/25 2:51:29 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Corcept Therapeutics Incorporated

    10-Q - CORCEPT THERAPEUTICS INC (0001088856) (Filer)

    11/4/25 4:12:58 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CORT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $CORT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Overall Survival Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

    Data demonstrate a 35 percent reduction in the risk of death Both dual primary endpoints (progression-free and overall survival) were met, without the need for biomarker selection and without increased safety burden Relacorilant's New Drug Application (NDA) is under review by the U.S. Food and Drug Administration (FDA) as a treatment for patients with platinum-resistant ovarian cancer with a Prescription Drug User Fee Act (PDUFA) target action date of July 11, 2026 Relacorilant's Marketing Authorization Application (MAA) for patients with platinum-resistant ovarian cancer is also under review by the European Medicines Agency (EMA) Corcept Therapeutics Incorporated (NASDAQ:CORT)

    1/22/26 8:00:00 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism

    Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the U.S. Food and Drug Administration (FDA or the Agency) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism. While the FDA acknowledged that Corcept's pivotal GRACE trial met its primary endpoint and that data from the company's GRADIENT trial provided confirmatory evidence, the Agency

    12/31/25 8:00:00 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update

    Revenue of $207.6 million, compared to $182.5 million in third quarter 2024 Modified 2025 revenue guidance of $800 – $850 million Net income of $19.7 million, compared to $47.2 million in third quarter 2024 Cash and investments of $524.2 million at September 30, 2025 Oncology development programs expanded to include new studies in Earlier-stage ovarian, endometrial, cervical and pancreatic cancers, in combination with chemotherapy Broad range of solid tumors, in combination with immunotherapy Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic

    11/4/25 4:05:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Hunt Hazel exercised 150,000 shares at a strike of $3.88 and covered exercise/tax liability with 77,968 shares, increasing direct ownership by 39% to 255,437 units (SEC Form 4)

    4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)

    2/11/26 5:26:28 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Development Officer Guyer William exercised 20,000 shares at a strike of $21.65 and sold $817,334 worth of shares (20,000 units at $40.87) (SEC Form 4)

    4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)

    2/5/26 5:42:50 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Baker G Leonard Jr exercised 140,000 shares at a strike of $11.49 (SEC Form 4)

    4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)

    1/29/26 4:10:05 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CORT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Corcept Therapeutics downgraded by Wolfe Research with a new price target

    Wolfe Research downgraded Corcept Therapeutics from Peer Perform to Underperform and set a new price target of $30.00

    12/31/25 9:53:16 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS initiated coverage on Corcept Therapeutics

    UBS initiated coverage of Corcept Therapeutics with a rating of Neutral

    12/16/25 8:47:55 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on Corcept Therapeutics

    Wolfe Research initiated coverage of Corcept Therapeutics with a rating of Peer Perform

    11/18/25 8:21:50 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CORT
    Leadership Updates

    Live Leadership Updates

    View All

    Corcept Appoints Roberto Vieira as President, Oncology

    MENLO PARK, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the appointment of Roberto Vieira as President, Oncology. He will report to Joseph K. Belanoff, MD, Corcept's Chief Executive Officer, and join the company's Executive Team. Mr. Vieira joins Corcept from Mirati Therapeutics, Inc., where he served as Senior Vice President of U.S. Commercial until earlier this month. At Mirati, Mr. Vieira built the U.S. commercial o

    1/29/24 8:00:00 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corcept Appoints Monica Tellado as President, Emerging Markets

    MENLO PARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism, and neurology disorders by modulating the effects of the hormone cortisol, today announced the appointment of Monica Tellado as President, Emerging Markets. She will report to Joseph K. Belanoff, MD, Corcept's Chief Executive Officer, and join the company's Executive Team. Ms. Tellado's prior role was at Heartflow, where she served as Chief Financial Officer. Before joining Heartflow, Ms. Tellado spent 19 years in ascending leadership roles at Gilead Science

    11/1/23 8:00:00 AM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corcept Therapeutics Announces Appointment of Three Senior Leaders

    MENLO PARK, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe endocrine, metabolic, oncologic and neurological disorders by modulating the effects of the hormone cortisol, today announced the appointment of three individuals to Commercial and Development leadership roles. Daniel Einhorn, MD, FACP, FACE, has joined Corcept as Vice President, Endocrine Strategy; Amiel Balagtas has joined as Vice President, Development Operations; and Lyndah Dreiling, MD, has joined as Vice President, Global Oncology Development. Dr. Einhorn will report to Sean Maduck, Presid

    4/7/22 4:05:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CORT
    Financials

    Live finance-specific insights

    View All

    Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update

    Revenue of $207.6 million, compared to $182.5 million in third quarter 2024 Modified 2025 revenue guidance of $800 – $850 million Net income of $19.7 million, compared to $47.2 million in third quarter 2024 Cash and investments of $524.2 million at September 30, 2025 Oncology development programs expanded to include new studies in Earlier-stage ovarian, endometrial, cervical and pancreatic cancers, in combination with chemotherapy Broad range of solid tumors, in combination with immunotherapy Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic

    11/4/25 4:05:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

    Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report third quarter financial results and provide a corporate update on November 4, 2025. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number and a unique access PIN. Each access PIN will accommodate one caller. Additionally, a listen-only webcast will be available by clicking here. A replay of the call will be available on the Investors / Events tab of Corcept.com. About Corcept Therape

    10/28/25 4:05:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

    Revenue of $194.4 million, compared to $163.8 million in second quarter 2024 Modified 2025 revenue guidance of $850 – $900 million Net income of $35.1 million, compared to $35.5 million in second quarter 2024 Cash and investments of $515.0 million at June 30, 2025 Acquired $115.4 million of Corcept common stock in second quarter 2025 Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended June 30, 2025. Financial Results

    7/31/25 4:05:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CORT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Corcept Therapeutics Incorporated (Amendment)

    SC 13G/A - CORCEPT THERAPEUTICS INC (0001088856) (Subject)

    3/27/24 2:32:52 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Corcept Therapeutics Incorporated (Amendment)

    SC 13G/A - CORCEPT THERAPEUTICS INC (0001088856) (Subject)

    2/14/24 4:23:00 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Corcept Therapeutics Incorporated (Amendment)

    SC 13G/A - CORCEPT THERAPEUTICS INC (0001088856) (Subject)

    2/13/24 5:02:29 PM ET
    $CORT
    Biotechnology: Pharmaceutical Preparations
    Health Care